PMID- 26300488 OWN - NLM STAT- MEDLINE DCOM- 20160721 LR - 20220409 IS - 1791-3004 (Electronic) IS - 1791-2997 (Linking) VI - 12 IP - 4 DP - 2015 Oct TI - Baicalin alleviates diabetes‑associated cognitive deficits via modulation of mitogen-activated protein kinase signaling, brain‑derived neurotrophic factor and apoptosis. PG - 6377-83 LID - 10.3892/mmr.2015.4219 [doi] AB - Baicalin is an important active component of the medicinal herb Scutellaria baicalensis Georgi and has shown a variety of pharmacological actions. The present study aimed to evaluate the neuroprotective effects of baicalin against diabetes‑associated cognitive deficits (DACD) in rats and to elucidate the potential molecular mechanisms of action. A rat model of diabetes mellitus was prepared by intraperitoneal injection of streptozotocin. After the successful establishment of the diabetic rat model, baicalin (50, 100 and 200 mg/kg) or vehicle was administrated for seven weeks. Learning and memory function were assessed using the Morris water maze test. At the end of the experiment, the activities of acetylcholinesterase (AChE) and choline acetylase (ChAT) were determined using commercial kits. Furthermore, the expression of proteins involved in mitogen‑activated protein kinase (MAPK) cascades [extracellular signal‑regulated kinase (ERK), c‑Jun N‑terminal kinase (JNK) and p38], brain‑derived neurotrophic factor (BDNF) and apoptosis‑associated proteins [caspase‑3, B-cell lymphoma 2 (Bcl‑2) and Bcl-2-associated X protein (Bax)] were detected by western blot analysis. Caspase‑3 activity was also analyzed using a commercial kit. The results demonstrated that diabetic rats exhibited decreases in body weight, decreases in the percentage of time spent in the target quadrant and the number of times of crossing the platform in the water maze test, as well as decreases in neuronal survival, ChAT, phosphorylated (p)ERK, BDNF and Bcl‑2. Furthermore, diabetic rats showed increases in escape latency and mean path length in the water maze test, increases in the levels of hippocampal AChE, p‑JNK, p‑p38, caspase‑3 and Bax as well as plasma glucose. However, in diabetic rats treated with baicalin, all of the abovementioned observations were obviously reversed. The findings suggested that baicalin exerts neuroprotective effects against DACD via modulation of MAPK cascades, BDNF and apoptosis. FAU - Ma, Ping AU - Ma P AD - Department of Anatomy, Daqing Campus of Harbin Medical University, Daqing, Heilongjiang 163319, P.R. China. FAU - Mao, Xiao-Yuan AU - Mao XY AD - Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China. FAU - Li, Xiao-Lei AU - Li XL AD - Department of Pathology, College of Basic Medical Sciences, Daqing Campus of Harbin Medical University, Daqing, Heilongjiang 163319, P.R. China. FAU - Ma, Ying AU - Ma Y AD - Department of Pathology, College of Basic Medical Sciences, Daqing Campus of Harbin Medical University, Daqing, Heilongjiang 163319, P.R. China. FAU - Qiao, Yuan-Dong AU - Qiao YD AD - Department of Pharmacology, Daqing Campus of Harbin Medical University, Daqing, Heilongjiang 163319, P.R. China. FAU - Liu, Zhao-Qian AU - Liu ZQ AD - Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China. FAU - Zhou, Hong-Hao AU - Zhou HH AD - Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China. FAU - Cao, Yong-Gang AU - Cao YG AD - Department of Pharmacology, Daqing Campus of Harbin Medical University, Daqing, Heilongjiang 163319, P.R. China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150812 PL - Greece TA - Mol Med Rep JT - Molecular medicine reports JID - 101475259 RN - 0 (Bax protein, rat) RN - 0 (Blood Glucose) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Flavonoids) RN - 0 (Neuroprotective Agents) RN - 0 (bcl-2-Associated X Protein) RN - 347Q89U4M5 (baicalin) RN - 5W494URQ81 (Streptozocin) RN - EC 2.3.1.6 (Choline O-Acetyltransferase) RN - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases) RN - EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinases) RN - EC 3.1.1.7 (Acetylcholinesterase) RN - EC 3.4.22.- (Casp3 protein, rat) RN - EC 3.4.22.- (Caspase 3) SB - IM MH - Acetylcholinesterase/metabolism MH - Animals MH - Apoptosis/*drug effects MH - Blood Glucose/metabolism MH - Brain-Derived Neurotrophic Factor/*metabolism MH - Caspase 3/metabolism MH - Choline O-Acetyltransferase/metabolism MH - Cognition Disorders/*drug therapy MH - Diabetes Mellitus, Experimental/chemically induced/drug therapy MH - Extracellular Signal-Regulated MAP Kinases/metabolism MH - Flavonoids/*pharmacology MH - Hippocampus/drug effects/metabolism MH - JNK Mitogen-Activated Protein Kinases/metabolism MH - Male MH - Maze Learning/drug effects MH - Memory/drug effects MH - Mitogen-Activated Protein Kinases/*metabolism MH - Neuroprotective Agents/pharmacology MH - Rats MH - Rats, Wistar MH - Streptozocin MH - bcl-2-Associated X Protein/metabolism EDAT- 2015/08/25 06:00 MHDA- 2016/07/22 06:00 CRDT- 2015/08/25 06:00 PHST- 2014/10/24 00:00 [received] PHST- 2015/07/21 00:00 [accepted] PHST- 2015/08/25 06:00 [entrez] PHST- 2015/08/25 06:00 [pubmed] PHST- 2016/07/22 06:00 [medline] AID - 10.3892/mmr.2015.4219 [doi] PST - ppublish SO - Mol Med Rep. 2015 Oct;12(4):6377-83. doi: 10.3892/mmr.2015.4219. Epub 2015 Aug 12.